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M O R EXPANSION OF CD8'CD57+ lymphocytes
A is frequently reported after transplantation and/or in association with persistent or recurrent viral infections, such as cytomegalovirus (CMV) or human immunodeficiency virus (HIV).' As tested in vitro, a suppressor cell function of mitogen-induced B-and T-cell proliferation has been assigned to these cells, suggesting their contribution to the control of lymphocyte reactivity against viral antigens or to a tolerance state in engrafted
In contrast, CDS'CD57' lymphocytes have also been shown to act in vitro as precursors of lymphokine activated killer (LAK) cells.* However, the mechanism of action of those cells remains unknown, as well as their possible inhibitory activity on other immune functions.
In a previous study of virus-specific cytolytic T-cell responses in patients infected with HIV, we reported a late expansion of alveolar CDS'CD57' lymphocytes and demonstrated their ability to inhibit HIV-and HLA-specific cytolytic T lymphocyte (CTL) a~tivity.~ These data raised the question of a similar inhibitory function of cytolytic processes in allogeneic bone marrow transplant (BMT) recipients, in which this subset is increased. Here we present the first report indicating the inhibitory function of CD8TD57' peripheral blood lymphocytes (PBL) on cellmediated cytolysis in BMT recipients, which implicates a soluble less than lS, concanavalin A (ConA) binding inhibitor.
MATERIALS AND METHODS

Patienrs.
A total of 25 patients were studied from September 1989 to May 1990 after BMT from HLA-identical siblings for hematologic malignancies (24 cases) or severe aplastic anemia (one case). CMV infection was assessed on viral isolation in the blood or lungs. Blood bank donors (15) were tested as controls.
PBL were isolated by Ficoll-Hypaque gradient centrifugation (Pharmacia, Uppsala, Sweden) and either used immediately or cryopresewed.
A standard whole blood staining method was performed with the following monoclonal antibodies (MoAbs): anti-CD4-fluoro-isothiocyanate (FITC), anti-CDB-phycoerythrin (PE), and antiXD57-FITC (Immunotech, Marseille, France CTL and LAK cells were generated from normal PBL. Alloreactive anti-HLA CTL were tested after a 5-day allo-mixed lymphocyte culture (~IIo-MLC)~ against allogeneic Epstein-Barr virus (EBV)-transformed B-cell lines. LAK cells were tested against Daudi target cells after a 3-day culture in RPMI medium supplemented with 1 mmol/L sodium pyruvate, 2 mmoliL L-glutamine, 10% fetal calf serum plus 100 UimL recombinant interleukin-2 (rIL-2; Boerhinger-Ingelheim, Grenoble, France), or phytohemagglutinin-P (PHA-P) (1 &mL; Welcome, Paris, France). The 4-hour "Cr release assays (CRA) were performed at various killedtarget cells ratios. Lysis was expressed as percent of specific "Cr release; spontaneous "Cr release varied from 12% to 25% of total incorporated radioactivity. For inhibition assays of cytolytic activity, suppressor and control cells or SN were added to killer cells at various ratios at the onset of the CRA. Percentage of inhibition was calculated as follows: Proliferation assays. Normal PBL were incubated 3 days with or without PHA-P 1 &mL, or in microtiter plates precoated with anti-CD3 MoAb (UCHT1; a gift from P. Beverley, London, UK) in RPMI-supplemented medium. Cells were pulsed with 1 KCi ('H)TdR (5 Ci/nmol; CEA, Orsay, France) for the last 18 hours. For inhibition assays of proliferation, dilutions of SN from purified CD8TD57' or control PBL were added at day 0 of the cultures. Percentage of inhibition was calculated as follows:
-(cpm from responder cells alone + SN)
-(cpm from responder cells alone -SN)
-
Glycerol gradient centrijitgation and Cod-afiniiy chromatography. Concentrated SN ( 4~) from CD8TD57' or CD57-cells were layered onto either: (1) linear (5% to 20%) glycerol gradients, centrifugation was performed at 50,000 rpm and 4°C for 18 hours, sedimentation coefficients were determined by using glucose oxydase (7, 9 sedimentation [SI) and peroxydase (3, 6s) as standards; or (2) on a column of ConA-sepharose (Pharmacia, France) presaturated with bovine serum albumin (BSA; Sigma, St Louis, MO) and equilibrated at pH 7.6. After elimination of unbound material, specifically adsorbed compounds were eluted with 1 molL methyl-a-D-mannopyranoside (Sigma). Fractions (200 KL) were dialyzed before being tested for inhibition of LAK cell activity.
RESULTS
CD8'CD57' PBL from BMT recipients inhibit cellmediated cytolysis.
PBL from 25 BMT recipients were prospectively analyzed for coexpression of the CD8 and CD57 antigens defining a group (I) of 13 patients with a major increase of the CD8'CD57+ subset ( > 15%, mean 31% * 12%, ranges 15% to 59%) as compared with 12 patients in group I1 ( < 15%, mean 6% * 5%, ranges 1% to 15%) and with normal controls (mean 7% 2 5%, ranges 1% to 12%) (P < .Ol). A CMV infection was significantly more frequent in group I (7 of 13) than in group I1 (1 of 12) (P < .05), but no differences could be detected concerning the delay from BMT, acute graft-versus-host disease (GVHD), or chronic GVHD (data not shown),
We then investigated whether CD8TD57' PBL isolated from allo-BMT patients could inhibit HLA-specific cytolytic activities. Allospecific CTL were first generated from normal controls against appropriate allogeneic EBVtransformed B-cell lines. The addition of group I PBL to a constant number of CTL at the onset of CRA induced a dose-dependant inhibition of the allospecific cytolysis ( Fig  1A) . This inhibition of allogeneic CTL was not restricted by major histocompatibility complex (MHC) antigens and could be observed by using PBL from nine distinct HLAmismatched group I patients (data not shown). Such a lack of MHC restriction prompted us to look for a similar suppression of non-antigen-specific cytolysis: rIL-2-driven LAK cell activity was similarly inhibited by PBL from a group I patient (Fig lB) , as were inhibited PHA-activated killer cells and natural killer (NK) cells (data not shown). Of note, the PBL from group I patients lacked spontaneous cytolytic activity on K562 and Daudi target cells. Furthermore, sorting experiments allowed us to determine the phenotype of such inhibitory PBL. Indeed, the inhibition of CTL or LAK cytolysis was specifically mediated by CDg'CD57' FACS-sorted or CD57' immunobead-purified PBL (Fig lB) , but not by control CD57-cells. Altogether, these data demonstrate that CD8TD57' PBL expanded in vivo in allo-BMT recipients mediate a novel inhibitory activity on both allo-specific and non-antigen-specific cytolytic activities.
Phenotypic characterization of suppressor CD8'CD57+ PBL.
To further characterize the cell surface markers of CDFCD57' PBL from allo-BMT recipients, a three-color IF analysis was performed on CD8TD57' cells. As shown in Table 1 , 95% to 100% CD8TD57' cells exhibit the pan-T CD2, CD7, and CD5 antigens, and 92% to 94% display the CD3-TcRaP complex. In contrast, 92% to 93% do not express the CD56 NK cell marker, and this is in accordance with the absence of spontaneous NK activity. The analysis of T-cell activation markers shows that 23% to 39% of CD8TD57' cells were HLA-DR', contrasting with the lack of expression of CD25 (0.6% to 0.7%). Finally, all 
CD8' CD57' PEL'S SOLUBLE INHIBITOR OF CYTOLYSIS
CD8TD57' PBL display the CDw29 antigen and 56% to 58% display the CD45, antigen, suggesting a possible coexpression of both antigens on CD8TD57' cells.
CD8'CDST PBL release a soluble nonspecific inhibitory factor. The nonspecific, short-term inhibitory activity of CD8'CD57+ PBL suggested the release of a soluble inhibitor of cytolytic functions. Supernatants were then produced from purified CD8TD57' PBL in a 4-hour culture in serum-free medium. Those SN mediated a dose-dependant inhibition of differentiated killer cell activity similar to that observed with the CD8+CD57' cells (Fig 2A) . We then looked for a similar activity of CDVCD57' SN on T-cell proliferation. Figure 2B shows that the addition of CD8'CD57+ SN at day 0 of culture inhibits both PHA-and anti-CD3-induced proliferation of normal PBL as well as nonspecific or antigen-specific killer cell activity.
To define the target of such a soluble inhibitory activity, cytolytic effector and target cells were separately incubated in CD8'CD57'SN, then washed before CRA. As shown in Fig 2C , Daudi target cells remained sensitive to killer cells after preincubation, whereas LAK cells lost 66% of their cytolytic activity for the subsequent 4 hours. These SN were not lytic because we observed a 90% viability of LAK and target cells after a 4-hour incubation in CD8'CD57' SN (data not shown). Furthermore, we could demonstrate that prostaglandin E, (PGE,) was not responsible for the inhibitory effect described here because the CD8'CD57' effect was not abolished when CD8TD57' PBL were treated by inhibitors of PG synthesis, such as indomethacin (data not shown). These data indicate that the soluble inhibitor present in CD8'CD57' supernatants is acting at the effector killer cell level.
Preliminary characterization of the soluble inhibitor released fiom CD8+CD57+ PBL. The coefficient of sedimentation 80 . (CS) of the CD8TD57' soluble factor was then defined by fractionation on the glycerol gradient of SN from both purified CD8'CD57' and CD57-cells; resulting fractions were tested for their inhibitory activity on LAK cellmediated cytolysis indicating a CS less than 1s (Fig 3A) because the inhibitory activity of CD8TD57' SN was present in fractions N 17 and 18, but not in fractions N 10 through 16 or 19 through 26 from CD8TD57' SN or in fractions from CD57-SN. Finally, we tested the ability of the CD8TD57' soluble inhibitory activity to bind to ConA lectin. We applied a fourfold concentrated CD8'CD57' SN to a ConA column previously saturated with BSA. As shown in Fig 3, the inhibitory activity totally disappeared in the unbound fractions, whereas it could be specifically eluted after addition of methyl-a-D-mannoside. Altogether, these data indicate that the CD8'CD57+ lymphocyte inhibitory activity should be mediated by a glycosylated, low molecular weight soluble inhibitor.
DISCUSSION
This study was undertaken to investigate the ability of CD8TD57' lymphocytes from allo-BMT recipients to inhibit cell-mediated cytolytic activities, which are supposed to play a major role in a context of transplantation.
Our results show that sorted CD8TD57' PBL from allo-BMT patients not only lack spontaneous cytolytic activity against NK and LAK target cells, but also clearly inhibit both HLA-specific and non-antigen-specific killer cell activity. These data, together with our previous results obtained in HIV-infected patients: suggest that CD8'CD57' cells, lacking both HLA restriction and antigen specificity, are likely to interact with killer cells at a common step of the cell-mediated cytolytic processes, independently of the antigen recognition events. This suppression of cytolytic activity is mediated by a soluble inhibitor present in supernatants from sorted CD8'CD57' cells. Furthermore, the CDX'CD57' cellmediated suppression of B-and T-cell proliferation already observed is also likely to be mediated by the same CDVCD57' inhibitory molecule, because CDX'CD57' SN also inhibit the anti-CD3 or mitogen-induced T-cell proliferation. Our data indicate that CDVCD57' cells do not confer to target cells a state of resistance to lysis, but rather induce an impairment of the cytolytic effector cell function. Moreover, the viability of LAK and Daudi cells after incubation in CDX'CD57' SN argues against a lytic mechanism responsible for this inhibition. Finally, the inhibitory activity of CDX'CD57' SN can be detected in the less than lS, ConA-binding fractions, suggesting the responsibility of a mannosylated, low molecular weight molecule in this phenomenon and allowing further biochemical characterization. This soluble inhibitor differs from other known inhibitory or immunoregulatory molecules,'"~" such as transforming growth factor (TGF) or PGE,, as shown by its resistance to PGE, synthesis inhibition or to TGFP neutralization. To our knowledge, these original data constitute the first report on the mechanism of action of CDX'CD57' lymphocytes isolated in BMT patients and add to the complexity of functions mediated by such T cells.
Interestingly, CD8+CD57' lymphocytes display the CD3-TcRaP complex, raising the question of the functionality of this complex, as previously suggested by the ability of CDX'CD57' cells to generate in vitro an LAK cell function on a CD3 stimulation.'.'* Whether this killer function does occur in vivo is still unknown, but it should be emphasized that it is not detectable in vitro in nonstimulated CDg'CD57' PBL from BMT recipients. Of note is the presence of the CDw29 antigen and a possible coexpression of the CD45, antigen, suggesting that CDX'CD57' cells might have been primed in vivo. Finally, the CD8'CD57' PBL increase is usually associated with clinical conditions characterized by high antigenic stimulation, such as either persistent CMV, EBV, or HIV infections, or transplant^.'.^ Contrasting with several reports,*'" we could not see a relationship between the increase of such suppressor cells and GVHD, but we could observe a significant association with CMV infection, as previously mentioned. ' Whatever their induction mechanism, the in vivo relevance of the inhibitory activity mediated by CD8TD57' cells remains to be determined. Further studies of the inhibitor released by CD8TD57' cells, currently in progress in our laboratory, should help us to better define the inhibition of lymphocytic functions described here and the CDX'CD57' cells' implication in an in vivo control of BMT recipients' immune status. 
